Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07308275

Longitudinal Evaluation of Direct Neurotization Technique in Breast Reconstruction With Fully Autologous Components

This clinical trial aims to evaluate whether direct neurotization using fully autologous components during autologous breast reconstruction improves postoperative breast sensation and sensory-related quality of life in women undergoing unilateral mastectomy. Direct neurotization involves coapting the recipient intercostal nerve to an autologous nerve graft placed within the flap to facilitate reinnervation.

The study's primary questions are:

1. Does direct neurotization using fully autologous nerve grafts improve cutaneous sensory recovery, as assessed by Semmes-Weinstein monofilament thresholds measured at standardized breast locations? 2. Does neurotization enhance patient-reported sensory outcomes and quality of life, as assessed by the BREAST-Q Sensation Module?

As secondary objectives, the study will assess whether biological predictors of nerve regeneration correlate with sensory outcomes. These include:

1. Neuregulin-1 (NRG1) expression in flap tissue biopsy; 2. Cross-sectional area of the recipient nerve fibres; 3. Breast morphometry measured at baseline and follow-up; 4. Intraepidermal nerve fibre density (IENFD) on skin biopsy.

Participants will be randomly assigned to receive either:

1. Neurotized autologous breast reconstruction using fully autologous graft components, or 2. Standard (non-neurotized) autologous breast reconstruction.

The study will compare these groups to determine whether neurotization accelerates or enhances the return of breast sensation over a 6-month follow-up period, with evaluations at 1 month, 3 months, and 6 months after surgery.

Participants will undergo:

1. Autologous breast reconstruction with or without direct neurotization as part of their planned cancer surgery. 2. Sensory testing using Semmes-Weinstein monofilaments at baseline, 1, 3, and 6 months. 3. Completion of BREAST-Q questionnaires evaluating breast sensation, symptoms, and quality of life at each follow-up visit.

3. Intraoperative tissue sampling for NRG1 analysis and nerve morphometry. 4. Skin biopsy (if applicable) to assess intraepidermal nerve fibre density. 5. Breast morphometry assessment using a breast morphometry measurement software tool.

This study seeks to provide high-quality evidence on the effectiveness of direct neurotization using fully autologous components in restoring breast sensation and to explore biological predictors that may influence sensory recovery after autologous breast reconstruction.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

dr. Ciptomangunkusumo National Hospital - Faculty of Medicine Universitas Indonesia

Jakarta Pusat, Jakarta Special Capital Region, 10430, Indonesia

Location contact

Ayu PB Sarena, MD, MPH

CONTACT

[email protected]

+6285121316121

Mohamad Rachadian Ramadan, MD, MRBS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients aged ≥18 years.
  • Patients with unilateral breast cancer who have undergone or will undergo unilateral mastectomy.
  • Patients undergoing breast reconstruction.
  • Patients with unilateral breast cancer regardless of adjuvant therapy status (receiving radiotherapy and/or chemotherapy or receiving no adjuvant therapy).
  • Willing to comply with all scheduled examinations and tissue sampling procedures.
  • Able and willing to provide written informed consent.

Exclusion criteria

  • History of peripheral neuropathy (e.g., diabetes mellitus with neuropathic complications).
  • Bilateral mastectomy.
  • Presence of skin or soft-tissue conditions of the breast that may interfere with sensory assessment.
  • Active smokers (use of tobacco, vape, or other nicotine products within 14 days prior to neurotization).
  • Refusal or inability to attend follow-up evaluations.

Treatment and study plan

Autologous Breast Reconstruction With Direct Neurotization

Procedure

The direct neurotization using fully autologous components procedures include:

  • Direct neurotization is carried out using fully autologous components, involving coaptation of the recipient nerve to an autologous nerve graft placed within the flap to facilitate reinnervation.
  • Surgical breast reconstruction is then completed using patient's own tissue

Autologous Breast Reconstruction without Neurotization

Procedure

Breast reconstruction is performed using autologous tissue without nerve coaptation or neurotization, according to standard surgical practice.

Primary outcomes

  1. Breast Sensation assessed by using Semmes-Weinstein Monofilament testing

    Time frame: 1, 3 and 6 months after Neurotization

    SWM thresholds at nine standardized points on the reconstructed breast will be measured using calibrated monofilaments, categorized into levels of normal touch, diminished light touch, diminished protective sensation, loss of protective sensation, and deep pressure only.

  2. Patient's Quality of Life assessed by using BREAST-Q® Sensation Module

    Time frame: 1, 3 and 6 months after Neurotization

    The patient reported outcomes will be recorded in BREAST-Q® Sensation Module to capture the sensation, breast symptoms, and quality of life impact of sensation loss.

Secondary outcomes

  1. Neuregulin 1 Expression

    Time frame: During procedure and 6 months after surgery

    NRG1 expression quantified by ELISA from flap tissue

  2. Nerve Cross-sectional Area

    Time frame: Measured during neurotization procedure

    Nerve cross-sectional area measured via histomorphometry/histopathology using the recipient nerve of the direct neurotization method

  3. Breast Morphometry

    Time frame: Before surgery and 1, 3, 6 months after surgery

    Breast morphometry assessed using a validated AR/3D application

  4. Intraepidermal Nerve Fibre Density (IENFD)

    Time frame: During procedure and 6 months after surgery

    IENFD quantified by counting PGP9.5-positive intraepidermal fibers per mm of epidermal length. Flap skin tissue samples will be taken using 3 mm punch biopsy

Study contacts

Contact information is provided by the study sponsor or research team.

Mohamad Rachadian Ramadan, MD., MRBS.

CONTACT

[email protected]

+62881082855557

Sponsors and collaborators

Lead sponsor

Fakultas Kedokteran Universitas Indonesia

Other

Registry information

Official study title

Longitudinal Evaluation of Direct Neurotization Technique in Breast Reconstruction With Fully Autologous Components: An Assessment of BREAST-Q Sensation Module, Cutaneous Pressure Threshold, Neuregulin 1 (NRG1) Expression, Nerve Fiber Cross-sectional Area, Intraepidermal Nerve Fiber Density (IENFD), and Breast Morphometry

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 29, 2025
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.